Simplify Logo

Full-Time

Principal Scientist

Dmpk

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Hardware
Biotechnology
Healthcare

Compensation Overview

$198k - $242kAnnually

Expert

San Bruno, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • PhD degree in Pharmacokinetics, Drug Metabolism, or a related life sciences degree with 12+ years of experience in small molecule development; industry experience is highly preferred, but will consider commensurate postdoc experience
  • Demonstrated experience designing and conducting experiments in support of DMPK lead optimization and candidate selection activities
  • Hands-on experience designing, analyzing and interpreting drug metabolism and PK studies.
  • Expertise and experience in the following areas: State of the art bioanalysis by LC/MS/MS and related techniques, Metabolite identification and reactive metabolite chemistry, Hands on ADME assays like CYP enzymes inhibition, induction and/or transporters assays, Principals, theories and approaches to understand pharmacokinetics, drug disposition and drug interactions, Application of modeling and prediction methods using software packages, Familiarity with a range of laboratory automation instrumentation including robotic liquid handlers.
Responsibilities
  • Lead and manage in-vivo and in-vitro ADME/PK studies to support drug discovery and early development of small molecules.
  • Collaborate with medicinal chemists to design drug candidates that avoid metabolic liabilities and evaluate them based on potency, ADME profile, and drug-drug interaction liabilities.
  • Mentor and motivate the in-house DMPK team, fostering a collaborative and proactive environment.
  • Provide technical expertise and support in the use of standard PK and PD data analysis software, including Phoenix WinNonlin, NONMEM, and similar tools.
  • Deep understanding of drug metabolism and how contribute in drug exposure. Preferable hands on experience with hepatocytes MetID.
  • Evaluate and interpret in vitro and in vivo DMPK data, working with DMPK colleagues to design studies that address key project issues.
  • Provide scientific expertise on experimental design, data analysis, interpretation, reporting, and leading the PK/PD analysis for the assigned projects.
  • Perform and lead non-compartmental PK modeling
  • Assist in troubleshooting and routine sample analysis of established bioanalytical methods and develop/optimize method of analysis as needed.
  • Contribute to protocols and reports for IND submissions
  • Manage and troubleshoot DMPK activities and instrument/assay issues as they arise.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.